BCL2 and B-cell chronic lymphocytic leukemia: Herein, we mainly discuss the BCL-2-specific BH3 mimetic venetoclax, the first United States Food and Drug Administration (FDA)-approved BCL-2 inhibitor, which has achieved revolutionary therapeutic advances in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).